罗氏的创新药物维泊妥珠在弥漫性大B细胞淋巴瘤（DLBCL）治疗领域取得了显著突破，成为近年来备受瞩目的明星产品。这款CD79b ADC药物不仅代表了罗氏在血液瘤领域的深厚积累，更体现了其对中国患者持续不断的关怀与承诺。 自2020年起，维泊妥珠在海南博鳌乐城国际医疗旅游先行区开始临床应用，迅速吸引了国内患者的关注。经过数年的努力，这款药物终于在2023年1月获得了国家药品监督管理局（NMPA）的批 ...

文｜氨基观察 “维泊妥珠将会继续引领一线弥漫性大 B 细胞淋巴瘤（DLBCL）市场”，对于这款CD79b ADC药物，罗氏向来野心勃勃，并在公开场合表明这一预期。

A new study published in the Journal for Immunotherapy of Cancer has presented a promising advancement in chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL).

Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers BV combined with Len + R demonstrated significant improvements in overall survival (OS; 37% reduced risk of ...

Most DLBCL cases fall into the DLBCL, NOS category. Within this category, researchers have identified 2 main cell-of-origin (COO) molecular subtypes using gene expression profiling: germinal center ...